Stock A003220 DAEWON PHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

All News Daewon Pharmaceutical Co., Ltd.

Equities

A003220

KR7003220001

End-of-day quote Korea S.E.
Other stock markets
 06:00:00 2024-05-20 pm EDT 		5-day change 1st Jan Change
14,940 KRW -0.53% Intraday chart for Daewon Pharmaceutical Co., Ltd. -1.71% -4.60%
Mar. 14 Daewon Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
2023 SD Biotechnologies Co., Ltd. announced that it has received KRW 65 billion in funding from Koino Co.Ltd., Focus Asset Management Co., Ltd., Daewon Pharmaceutical Co., Ltd. CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Daewon Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
SD Biotechnologies Co., Ltd. announced that it has received KRW 65 billion in funding from Koino Co.Ltd., Focus Asset Management Co., Ltd., Daewon Pharmaceutical Co., Ltd.
CI
SD Biotechnologies Co., Ltd. announced that it expects to receive KRW 65 billion in funding from Koino Co.Ltd., Focus Asset Management Co., Ltd., Daewon Pharmaceutical Co., Ltd.
CI
Daewon Pharmaceutical Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
SD Biotechnologies Co., Ltd. announced that it expects to receive KRW 40 billion in funding from Daewon Pharmaceutical Co., Ltd.
CI
Daewon Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
Tranche Update on Daewon Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on September 20, 2022.
CI
Tranche Update on Daewon Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on September 20, 2022.
CI
Daewon Pharmaceutical Co., Ltd.'s Equity Buyback announced on September 20, 2022, has expired with 361,402 shares, representing 1.71% for CNY 6,001.69 million.
CI
Daewon Pharmaceutical Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
CI
Daewon Pharmaceutical Co., Ltd. announces an Equity Buyback for 378,549 shares.
CI
Daewon Pharmaceutical Co., Ltd. authorizes a Buyback Plan.
CI
Daewon Pharmaceutical Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
CI
Daewon Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
Daewon Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021
CI
Daewon Pharmaceutical to Launch Osteoarthritis Drug in Russia
MT
List Biotherapeutics, Inc. announced that it expects to receive KRW 21.342007114 billion in funding from Daewon Pharmaceutical Co., Ltd., Korea Investment & Securities Co., Ltd., Investment Arm, and other investors
CI
South Korean Pharmaceutical Firms Rush to Develop COVID-19 Oral Pills
MT
Daewon Pharmaceutical Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021
CI
Daewon Pharmaceutical Co., Ltd. announced that it has received KRW 12 billion in funding from SUSUNG ASSET MANAGEMENT Co., Ltd., KB Securities Co., Ltd., Investment Arm
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. A003220 Stock
  4. News Daewon Pharmaceutical Co., Ltd.
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW